Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 15 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.74 Insider Own1.51% Shs Outstand192.74M Perf Week-11.21%
Market Cap198.52M Forward P/E- EPS next Y-0.88 Insider Trans-1.31% Shs Float189.83M Perf Month-22.56%
Income-91.17M PEG- EPS next Q-0.44 Inst Own61.93% Short Float15.67% Perf Quarter-31.33%
Sales21.73M P/S9.14 EPS this Y10.88% Inst Trans7.50% Short Ratio3.42 Perf Half Y-60.54%
Book/sh2.08 P/B0.50 EPS next Y45.28% ROA-16.08% Short Interest29.75M Perf Year-68.50%
Cash/sh0.95 P/C1.08 EPS next 5Y45.80% ROE-47.81% 52W Range0.88 - 5.53 Perf YTD-25.36%
Dividend Est.- P/FCF- EPS past 5Y15.14% ROI-20.06% 52W High-81.37% Beta0.78
Dividend TTM- Quick Ratio1.42 Sales past 5Y- Gross Margin-15.86% 52W Low17.18% ATR (14)0.13
Dividend Ex-Date- Current Ratio1.55 EPS Y/Y TTM87.79% Oper. Margin-1523.91% RSI (14)36.90 Volatility8.68% 9.06%
Employees- Debt/Eq1.36 Sales Y/Y TTM322.60% Profit Margin-419.62% Recom2.77 Target Price3.77
Option/ShortYes / Yes LT Debt/Eq1.04 EPS Q/Q29.93% Payout- Rel Volume0.88 Prev Close1.10
Sales Surprise-53.53% EPS Surprise5.67% Sales Q/Q17353.52% EarningsMar 26 BMO Avg Volume8.71M Price1.03
SMA20-19.70% SMA50-18.13% SMA200-59.87% Trades Volume7,660,914 Change-6.36%
Date Action Analyst Rating Change Price Target Change
Dec-11-23Downgrade HSBC Securities Hold → Reduce
Dec-08-23Upgrade Morgan Stanley Underweight → Equal-Weight $3 → $7
Oct-17-23Initiated Cantor Fitzgerald Neutral
Sep-06-23Initiated HSBC Securities Buy $4.21
Jul-19-23Upgrade BofA Securities Neutral → Buy $6 → $10
Jun-01-23Upgrade Barclays Equal Weight → Overweight $7 → $8
Apr-28-23Initiated JP Morgan Overweight $7
Mar-07-23Initiated Robert W. Baird Outperform $10
Aug-05-22Upgrade Barclays Underweight → Equal Weight
Aug-02-22Upgrade Raymond James Mkt Perform → Outperform $8
Apr-15-24 08:15AM
Apr-13-24 04:22PM
Apr-11-24 08:30AM
Apr-02-24 11:33AM
05:20AM Loading…
Mar-29-24 05:20AM
Mar-27-24 11:37AM
Mar-26-24 07:01AM
Mar-25-24 04:05PM
Mar-19-24 07:44AM
Mar-18-24 06:05PM
Mar-13-24 07:50AM
Mar-11-24 08:00AM
06:56PM Loading…
Mar-05-24 06:56PM
Jan-27-24 07:28AM
Jan-10-24 06:55AM
Jan-08-24 08:00AM
Jan-04-24 03:32PM
Jan-03-24 07:15AM
Jan-02-24 08:00AM
Dec-26-23 08:00AM
Dec-24-23 07:39AM
Dec-23-23 07:30AM
Dec-22-23 08:45AM
Dec-20-23 02:23PM
Dec-19-23 09:41PM
04:01PM Loading…
Dec-18-23 04:01PM
Dec-15-23 11:14AM
Dec-11-23 05:43AM
Dec-10-23 12:02PM
Dec-09-23 11:31AM
Dec-08-23 01:45PM
Dec-07-23 11:30AM
Dec-01-23 07:41AM
Nov-29-23 02:28PM
Nov-26-23 04:44PM
Nov-24-23 07:00AM
Nov-08-23 03:39PM
Nov-07-23 05:18PM
Nov-04-23 08:45AM
Nov-02-23 09:37AM
Oct-30-23 08:00AM
Oct-24-23 08:00AM
Oct-17-23 09:47AM
Sep-29-23 09:00AM
Sep-20-23 07:21AM
Sep-12-23 07:00AM
Sep-07-23 11:30AM
Sep-05-23 04:05PM
Aug-29-23 05:25AM
Aug-28-23 08:30AM
Aug-24-23 10:15AM
Aug-16-23 07:00AM
Aug-08-23 08:25AM
Aug-05-23 09:40AM
Jul-27-23 11:19AM
Jul-25-23 08:00AM
Jul-22-23 06:14AM
Jul-20-23 01:14AM
Jul-19-23 12:36PM
Jun-30-23 10:15AM
Jun-29-23 09:53AM
Jun-21-23 07:00AM
Jun-15-23 10:00AM
Jun-08-23 11:30AM
Jun-01-23 02:09AM
May-10-23 07:57AM
May-09-23 07:10AM
Apr-27-23 04:05PM
Apr-24-23 03:49PM
Apr-13-23 02:17PM
Apr-06-23 10:15AM
Apr-02-23 09:15AM
Mar-30-23 01:54PM
Mar-29-23 08:15AM
Feb-24-23 10:00AM
Feb-08-23 08:05AM
Feb-03-23 05:00AM
Jan-30-23 09:12AM
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Obenshain AndrewPresident and CEOMar 04 '24Sale1.536,0959,311279,998Mar 05 05:40 PM
Klima Thomas JSee RemarksMar 04 '24Sale1.534,5736,986124,840Mar 05 05:39 PM
Colvin Richard AChief Medical OfficerMar 01 '24Sale1.536,77010,342118,368Mar 05 05:40 PM
Vittiglio JosephChief Business & Legal OfficerFeb 05 '24Sale0.905,2174,70844,783Feb 06 04:07 PM
Klima Thomas JSee RemarksFeb 05 '24Sale0.902,7142,449129,413Feb 06 04:07 PM
Obenshain AndrewPresident and CEOFeb 05 '24Sale0.901,8791,696286,093Feb 06 04:07 PM
Obenshain AndrewPresident and CEOJan 05 '24Sale1.433,1624,520287,972Jan 09 04:05 PM
Colvin Richard AChief Medical OfficerJan 05 '24Sale1.42597845125,138Jan 09 04:05 PM
Krawtschuk ChristopherChief Financial OfficerDec 06 '23Sale4.524,52620,43745,474Dec 08 04:42 PM
Obenshain AndrewPresident and CEONov 03 '23Sale3.178072,555291,134Nov 03 04:10 PM
Colvin Richard AChief Medical OfficerNov 02 '23Sale2.982,3436,975125,735Nov 03 04:10 PM
Klima Thomas JSee RemarksSep 05 '23Sale3.799223,493132,127Sep 06 04:30 PM
Obenshain AndrewPresident and CEOAug 10 '23Sale3.5416,92959,956291,941Aug 10 05:00 PM
Klima Thomas JSee RemarksJun 02 '23Sale3.504,13014,451133,049Jun 06 04:06 PM